Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 58,00 € (+1,31 %). La médiane est de 60,09 € (+4,96 %).
| Acheter |
12 |
| Conserver |
16 |
| Vendre |
1 |
Actualités Accéder au fil d'actualités
Inspire Medical: management sees end of setbacks — growth expected to return in 2027
At the Wells Fargo conference, Inspire Medical said coding and reimbursement issues weighed on procedure volumes in 2026, but the company is operationally better positioned thanks to clearer Medicare rules and increasing acceptance of Inspire V. Second-quarter revenue fell about 7.5% but topped internal expectations and showed rising gross margins driven by product mix. With the $30 million efficiency program "Project Horizon", anticipated easing of reimbursement, and ongoing product development such as Inspire 6, management aims to return to revenue growth in 2027. » Plus sur de.investing.com
Inspire Medical exceeds Q2 forecasts and raises full-year outlook
Inspire Medical delivered an adjusted earnings per share of $0.14 and revenue of $200.6 million in the second quarter, beating consensus estimates despite a 7.6% year-over-year revenue decline due to coding and reimbursement issues. The stock rose sharply after the results as management highlighted improving trends in prior authorizations and stronger international performance. The company launched the restructuring plan "Project Horizon", plans to free up $30 million annually for growth investments, and raised its 2026 full-year guidance, while still expecting a third-quarter revenue decline of 8–10% with sequential improvement. Financial metrics show solid liquidity ($415 million cash) and no debt, although risks remain in executing reimbursement and restructuring measures. » Plus sur de.investing.com
Inspire Medical under pressure after downgrade over reimbursement uncertainty
Bank of America downgraded Inspire Medical from "Neutral" to "Underperform" and cut the price target from $53 to $39, saying a unified coding process and an official CPT code for Inspire V are not expected before early 2028. The company lowered its 2026 revenue outlook to $825–875 million and expects diluted EPS of $0.07–0.62, underscoring near-term revenue and earnings risks. CEO Tim Herbert said the company is working with stakeholders on solutions but expects persistent challenges through the end of 2026. The stock fell to new multi-year lows and is about 70% below last year’s level; the main recovery catalyst remains clarity on the reimbursement rules for Inspire V. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursDonnées financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 182,48 M | 4,61 % |
| Bénéfice brut | 157,02 M | 4,39 % |
| Bénéfice net | -21,54 M | 354,46 % |
| EBITDA | -17,54 M | 219,42 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 1,66 Md € |
Nombre d'actions | 28,97 M |
Plus haut/bas sur 52 semaines | 131,86 € - 34,89 € |
| Dividendes | Non |
Bêta | 0,65 |
Ratio P/E | 18,38 |
Ratio PEG | 0,14 |
Ratio P/B | 2,24 |
Ratio P/S | 2,10 |
Profil de l'entreprise
Inspire Medical Systems, Inc., une entreprise de technologie médicale, se consacre au développement et à la commercialisation de solutions mini-invasives destinées aux patients souffrant d'apnée obstructive du sommeil (AOS) aux États-Unis et à l'international. La société propose le système Inspire, une technologie de neurostimulation qui offre un traitement sûr et efficace de l'AOS modérée à sévère. Elle développe également une nouvelle solution en boucle fermée qui surveille en continu la respiration du patient et délivre une stimulation légère du nerf hypoglosse afin de maintenir les voies respiratoires ouvertes. La société a été constituée en 2007 et son siège social se situe à Golden Valley, dans le Minnesota.
| Nom | Inspire Medical Systems |
| PDG | Timothy Herbert |
| Siège social | Golden Valley,
mn États-Unis |
| Site web | |
| Secteur | Santé |
| Industrie | Technologies de la santé |
| Introduction en bourse | 03/05/2018 |
| Employés | 1 333 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NYSE | INSP |
Frankfurt | 2DR.F |
Düsseldorf | 2DR.DU |
München | 2DR.MU |
